Understanding the potential benefits of VUMERITY
In clinical trials, a medication called dimethyl fumarate was tested in people with relapsing-remitting MS. Dimethyl fumarate has the same active metabolite as VUMERITY® (diroximel fumarate).
Two
separate studies
Each study
lasted two years
Over 1,500
people
|
|
Shown to be effective in the three goals of relapsing MS treatment
Cut relapses
Relapses (also called flare-ups or exacerbations) can be disruptive. Reducing the risk of relapses should be one of the goals of treatment.
Although no relapsing MS medication completely gets rid of relapses, dimethyl fumarate (which has the same active metabolite as VUMERITY) has been shown to reduce relapses compared with placebo.
Dimethyl fumarate cut the risk of relapses
27% of people taking dimethyl fumarate had a relapse, compared with 46% taking placebo.
Dimethyl fumarate cut the number of relapses
Dimethyl fumarate cut the number of relapses by 53% compared with placebo (dimethyl fumarate 0.172, placebo 0.364).
Dimethyl fumarate cut the risk of relapses
29% of people taking dimethyl fumarate had a relapse, compared with 41% taking placebo.
Dimethyl fumarate cut the number of relapses
Dimethyl fumarate cut the number of relapses by 44% compared with placebo (dimethyl fumarate 0.224, placebo 0.401).
Delay the progression of
physical disability
When you have relapsing MS, you know how important it is to stay as active and mobile as you possibly can.
Dimethyl fumarate (which has the same active metabolite as VUMERITY) was shown to delay the progression of physical disability, which is an important goal of treatment.
Disability progression was less likely
38% less likely
16% of people taking dimethyl fumarate experienced disability progression, compared with 27% taking placebo.
21% less likely
13% of people taking dimethyl fumarate experienced disability progression, compared with 17% taking placebo.
It cannot be determined if this change was due to dimethyl fumarate.
Slow the development of
brain lesions
The link between brain lesions and the progression of relapsing MS has not been confirmed. However, lesions can happen without you feeling them, which may be a sign that the disease is active. Lesions revealed on an MRI scan may help your healthcare provider determine how well your treatment is working. Talking to your healthcare provider about the results of your MRI could help with the management of your relapsing MS.
How dimethyl fumarate may help
To understand the impact of dimethyl fumarate (which has the same active metabolite as VUMERITY) on brain lesions, researchers looked at lesions using 3 different MRI techniques to determine the age and stage of the lesions. Based on all 3 measures, people taking dimethyl fumarate had fewer lesions compared with those taking placebo.
|
|
|
|
|
|
